[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 35909
1. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.
  • PURPOSE: The aim of the study was to analyze early effects and toxicity of salvage high dose rate brachytherapy for local recurrences of adenocarcinoma of the prostate after external beam radiotherapy (EBRT).
  • MATERIAL AND METHODS: In MCS Memorial Institute of Oncology in Gliwice a research programme on salvage HDR brachytherapy for local recurrences of prostate cancer treated previously with EBRT has been ongoing since February 2008.
  • Only in two patients grade 1 toxicity for rectum was observed.
  • In one patient grade 2 rectal toxicity was observed, and one had urethral stricture.
  • CONCLUSIONS: Salvage brachytherapy for localized prostate cancer (3 × 10 Gy every 14 days) seems to be a safe and well tolerated procedure.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


2. Corrigendum to "A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1984". Mol Ther; 2009 Jul;17(7):1302

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corrigendum to "A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1984".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28178478.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Published Erratum
  • [Publication-country] United States
  •  go-up   go-down


3. Guan Y, Ramasamy Reddy K, Zhu Q, Li Y, Lee K, Weerasinghe P, Prchal J, Semenza GL, Jing N: G-rich Oligonucleotides Inhibit HIF-1α and HIF-2α and Block Tumor Growth. Mol Ther; 2010 Jan;18(1):188-197
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HIF-1α subunit, which is regulated by O<sub>2</sub>-dependent hydroxylation, ubiquitination, and degradation, has been identified as an important molecular target for cancer therapy.
  • We have rationally designed G-rich oligodeoxynucleotides (ODNs) as inhibitors of HIF-1α for human cancer therapy.
  • JG243 and JG244 dramatically suppressed the growth of prostate, breast, and pancreatic tumor xenografts.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178550.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Lopez S, Simon JM, Mazeron JJ: [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate]. Bull Cancer; 2009 Mar;96(3):261-70
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
  • [Transliterated title] Hormono-radiothérapie des adénocarcinomes non métastatiques de la prostate.
  • Non-metastatic adenocarcinoma of prostate can be cured in the vast majority of cases with surgery and/or external or interstitial radiotherapy.
  • Analysis of results of recent randomised trials comparing this association and exclusive radiotherapy allows for validating concept of combined radiotherapy and hormone therapy in locally advanced adenocarcinoma of prostate, while many questions should be more clearly answered.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / radiotherapy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Chemotherapy, Adjuvant. Combined Modality Therapy / methods. Gonadotropin-Releasing Hormone / analogs & derivatives. Humans. Male. Neoplasm Recurrence, Local / prevention & control. Prostate-Specific Antigen / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318304.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 40
  •  go-up   go-down


5. Lemaître L, Villers A, Mouton D, Puech P: [Transrectal ultrasound and biopsy of the prostate]. J Radiol; 2006 Feb;87(2 Pt 2):201-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transrectal ultrasound and biopsy of the prostate].
  • [Transliterated title] Echographie et biopsies de prostate.
  • This review describes the transrectal ultrasound (TRUS) features of prostate cancer (PC), discusses the role of TRUS in the detection of PC and defines the modalities of biopsies in patients with suspected PC, particularly concerning prevention of complications, the number of biopsies and the biopsy schemes ensuring an optimal cancer detection rate.
  • TRUS alone has limited potential to identify PC because of frequent multifocality of cancer within the prostate, the variable sonographic appearance of prostatic tumors, the poor specificity of focal US abnormalities, and the substantial percentage of isoechoic PC.
  • However, limitations in cancer detection have been appreciated, particularly a false-negative rate approaching 20%.
  • This high failure rate has led investigators to refine biopsy techniques to improve cancer detection and to increase the total number of cores.
  • Currently, recommendations include increasing the biopsy number to a minimum of 10-12 cores, including sampling of the lateral prostate.
  • Refinements in imaging technologies (power Doppler sonography, microbubble intravenous sonographic contrast agents, and MR spectroscopy or dynamic contrast MR imaging) should eventually improve targeting of prostate needle biopsy and reduce false-negative biopsies.
  • [MeSH-major] Biopsy / methods. Prostate / pathology. Prostatic Neoplasms / pathology. Prostatic Neoplasms / ultrasonography
  • [MeSH-minor] Clinical Protocols. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / ultrasonography. Prostatitis / ultrasonography

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484945.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 15
  •  go-up   go-down


6. Rozet F, Cornu JN, Cussenot O, Fromont G, Hennequin C: [High-risk clinically localised prostate cancer]. Bull Cancer; 2010 Dec;97(12):1517-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-risk clinically localised prostate cancer].
  • [Transliterated title] Cancers de la prostate cliniquement localisés à haut risque de progression.
  • Localized prostate tumors have various clinical, biological and histopathologic characteristics that lead to different progression profiles.
  • High-risk localized prostate tumors have usually a worse outcome, but classic stratification predictive of outcome for prostate cancer is a matter of debate concerning its accuracy.
  • Diagnosis of high-risk prostate cancer has been improved by the use of MRI for local extension and risk of metastases.
  • Recent and major advances in the field of molecular biology are expected to provide new tools to better stratify men with prostate cancer at diagnosis.
  • Indeed, numerous biomarkers are in development, as a consequence of a better comprehension of molecular basis of prostate cancer.
  • New biomarkers (including circulating tumor cells) and genetic variations associated with prostate cancer aggressiveness should help us to define more precisely high-risk disease.
  • [MeSH-major] Neoplasm Recurrence, Local. Prostatic Neoplasms
  • [MeSH-minor] Androgen Antagonists / therapeutic use. Biomarkers, Tumor / analysis. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Combined Modality Therapy / methods. Drug Resistance, Neoplasm. Humans. Lymph Node Excision / standards. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Neoplastic Cells, Circulating. Positron-Emission Tomography. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatectomy. Radiation Tolerance

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220228.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


7. Reiffel JA: The Anticoagulated Atrial Fibrillation Patient Who Requires "Curative" Therapy for Prostate Carcinoma: a Bleeding Conundrum. J Atr Fibrillation; 2008 Dec;1(4):110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Anticoagulated Atrial Fibrillation Patient Who Requires "Curative" Therapy for Prostate Carcinoma: a Bleeding Conundrum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28496599.001).
  • [Journal-full-title] Journal of atrial fibrillation
  • [ISO-abbreviation] J Atr Fibrillation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Munbodh R, Chen Z, Jaffray DA, Moseley DJ, Knisely JPS, Duncan JS: Automated 2D-3D registration of portal images and CT data using line-segment enhancement. Med Phys; 2008 Oct;35(10):4352-4361

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In prostate radiotherapy, setup errors with respect to the patient's bony anatomy can be reduced by aligning 2D megavoltage (MV) portal images acquired during treatment to a reference 3D kilovoltage (kV) CT acquired for treatment planning purposes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28541619.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 2D-3D image registration / Anatomy / Computed tomography / Cone beam computed tomography / Digital radiography / Edge enhancement / Image registration / Medical image segmentation / Medical imaging / Portals / Radiation therapy / Radiography / Reconstruction / Registration / Treatment planning / computerised tomography / cone beam CT / diagnostic radiography / image enhancement / image reconstruction / image registration / medical image processing / phantoms / portal image / prostate radiotherapy / radiation therapy / setup verification
  •  go-up   go-down


9. Chytyk K, McCurdy B: Sci-Thurs PM: Delivery-04: Comprehensive fluence model for absolute portal dose image prediction in IMRT pre-treatment verification. Med Phys; 2008 Jul;35(7Part2):3399

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These measured profiles were used to determine the fluence model parameters and the resulting model was tested on prostate and oropharyngeal IMRT fields.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512809.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Amorphous semiconductors / Collimators / Dosimetry / Drug delivery / Image guided radiation therapy / Intensity modulated radiation therapy / Medical imaging / Multileaf collimators / Radiation treatment
  •  go-up   go-down


10. McCurdy B, Müller L, Backman E, Asuni G, Venkataraman S, Fleming E, Jensen M, urRehman F, Pistorius S: Poster - Thurs Eve-33: Initial implementation of a novel, measurement-based IMRT QA method. Med Phys; 2008 Jul;35(7Part2):3407

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The RPC Head&Neck phantom and two clinical prostate cases have been examined to date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512799.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Computer software / Dosimetry / Electric measurements / Intensity modulated radiation therapy / Linear accelerators
  •  go-up   go-down


11. Jiang R, Barnett R, Chow J: Poster - Thurs Eve-13: Modeling the effect of organ motion on cumulative rectal dose using EUD. Med Phys; 2008 Jul;35(7Part2):3403-3404

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rectal positional variations were measured fraction-to-fraction from MV EPI for 20 prostate patients implanted with gold seeds.
  • Five-field (5F) and seven-field (7F) IMRT plans for prostate patients were constructed with prescribed dose 78 Gy/39 fractions using a Pinnacle<sup>3</sup> treatment planning system.
  • The NTCP decreased with the increasing of dose gradient between the prostate and rectum for 5F and 7F IMRT plans.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512822.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Environmental impacts / Gold / Intensity modulated radiation therapy / Medical imaging / Medical treatment planning / Portals
  •  go-up   go-down


12. Liu W, Qian J, Hancock SL, Xing L, Luxton G: Clinical development of a failure detection-based online repositioning strategy for prostate IMRT-Experiments, simulation, and dosimetry study. Med Phys; 2010 Oct;37(10):5287-5297

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical development of a failure detection-based online repositioning strategy for prostate IMRT-Experiments, simulation, and dosimetry study.
  • PURPOSE: To implement and evaluate clinic-ready adaptive imaging protocols for online patient repositioning (motion tracking) during prostate IMRT using treatment beam imaging supplemented by minimal, as-needed use of on-board kV.
  • (1) Use cine-MV imaging and online-updated characterization of prostate motion to detect target motion that is potentially beyond a predefined threshold and (2) use paired MV-kV 3D localization to determine overthreshold displacement and, if needed, reposition the patient.
  • Experiments were performed on a Varian Trilogy linac in clinical mode using a 4D motion phantom programed with prostate motion trajectories taken from patient data.
  • CONCLUSIONS: This work demonstrated with a current clinical setup that substantial reduction of adverse targeting effects of intrafraction prostate motion can be realized.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524529.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Biomedical imaging / Dosimetry / Dosimetry/exposure assessment / IMRT / Image analysis / Image guided radiation therapy / Intensity modulated radiation therapy / Kinematics / Linear accelerators / Medical X-ray imaging / Medical image artifacts / Medical imaging / Multileaf collimators / Radiography / Real time information delivery / Simulation / Therapeutic applications, including brachytherapy / biological organs / biomedical equipment / diagnostic radiography / dosimetry / image motion analysis / image-guided radiation therapy / imaging dose reduction / intrafraction prostate motion / ionisation chambers / linear accelerators / medical image processing / motion tracking / object detection / on-board imaging / phantoms / portal imaging / radiation therapy
  •  go-up   go-down


13. García-Vicente F, Zapatero A, Floriano A, Cruz-Conde A, Pérez L, Marín A, Mínguez C, Torres JJ: Statistical analysis of dose-volume and dose-wall histograms for rectal toxicity following 3D-CRT in prostate cancer. Med Phys; 2005 Aug;32(8):2503-2509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical analysis of dose-volume and dose-wall histograms for rectal toxicity following 3D-CRT in prostate cancer.
  • The purpose of this paper is to determine the correlation between dose-volume histogram (DVH) and dose wall-histogram (DWH) in the evaluation of rectal complications for prostate cancer patients treated with three-dimensional conformal radiotherapy (3D-CRT).
  • A retrospective analysis of DVHs and DWHs of a subset of 25 prostate cancer patients treated with 3D-CRT was performed.
  • The present study confirms a high correlation (>80%) between DVH and DWH of the rectum following 3D-CRT for prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28523870.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Biomedical modeling / Cancer / Computed tomography / Conformal radiation treatment / Diseases / Dosimetry / Medical treatment planning / Probability theory, stochastic processes, and statistics / Radiation therapy / Radiation treatment / Statistical analysis / Therapeutics / Treatment strategy / biological organs / cancer / dosimetry / radiation therapy / regression analysis / tumours
  •  go-up   go-down


14. Mestrovic A, Nichol A, Clark B, Otto K: Sci-Fri AM: YIS-06: On-line adaptive radiation therapy based on the intra-fractional digital tomosynthesis images. Med Phys; 2008 Jul;35(7Part3):3411

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To test our system, a model representing typical prostate, bladder and rectum anatomy was generated.
  • To simulate prostate deformations, three clinically relevant deformations (small, medium and large) were modeled by systematically deforming the original anatomy.
  • RESULTS: Based on the dose-volume constraints from the RTOG 0415 prostate protocol, the original treatment plan would have been clinically unacceptable for all three deformations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512903.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adaptive radiation therapy / Anatomy / Digital tomosynthesis mammography / Dosimetry / Edge detection / Image reconstruction / Medical image reconstruction / Medical image segmentation / Medical imaging / Radiation treatment
  •  go-up   go-down


15. Wallis L: Anewline in men's talk. Nurs Stand; 2005 Jan 19;19(19):16-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ' Ms Spickett is a urology nurse specialist who works for the Prostate Cancer Charity (PCC).
  • She is talking to the wife of a man in the final stages of terminal prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006525.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Vaitheeswaran R, Sathiya Narayanan VK, Bhangle JR, Nirhali A, Kumar N, Basu S, Maiya V: An algorithm for fast beam angle selection in intensity modulated radiotherapy. Med Phys; 2010 Dec;37(12):6443-6452

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the efficiency of the algorithm was examined in three clinical cases (prostate, pancreas, and head and neck) in terms of DVH and dose distribution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524935.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Annealing / Cancer / Dose-volume analysis / Dosimetry / Intensity modulated radiation therapy / Kidneys / Numerical solutions / Optimization / Photons / Researchers / Treatment strategy / beam angle selection / beam angles / dosimetry / intensity modulated radiotherapy (IMRT) / intensity modulation / inverse planning / kidney / optimisation / phantoms / radiation therapy / radiotherapy
  •  go-up   go-down


17. Dickstein RJ, Kreshover JE, Milose JC, Gignac GA: Metastatic prostate cancer at diagnosis: Clinical presentation in the post-PSA era. J Clin Oncol; 2009 May 20;27(15_suppl):e16159

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate cancer at diagnosis: Clinical presentation in the post-PSA era.
  • : e16159 Background: Prostate cancer (CaP) has varying biologic behavior.
  • Prostate-specific antigen (PSA) screening dramatically diminished the presentation of patients (pts) with metastatic CaP from 5.6% in 1990 to 1.5% in 2003 as evidenced by the CaPSURE database.
  • Our institution has a uniquely diverse demographic and socioeconomic population and we sought to identify pts with metastatic CaP at diagnosis to evaluate contributing factors.
  • Forty-seven pts (77%) underwent prostate biopsy of which 33 (70%) had high grade (Gleason ≥ 8) tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Cescon DW, Canil C, Le LW, Tannock IF: Use of the Prostate Cancer-specific Quality of Life Instrument (PROSQOLI) in clinical practice. J Clin Oncol; 2009 May 20;27(15_suppl):e20569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of the Prostate Cancer-specific Quality of Life Instrument (PROSQOLI) in clinical practice.
  • : e20569 Background: Improvement of quality of life (QOL) is a major therapeutic goal for men with advanced prostate cancer (APC).
  • Prostate cancer-specific symptoms were poorly documented in clinical notes; improved recording of symptoms might be facilitated by the use of a tool such as the electronic touch-screen PROSQOLI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961125.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Lin D, Smith MR, Morton RA, Steiner MS: Use of age and BMD to predict fracture risk in men on androgen deprivation therapy. J Clin Oncol; 2009 May 20;27(15_suppl):9517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a randomized double blind placebo controlled trial in 1382 men with histologically confirmed prostate cancer on ADT.
  • CONCLUSIONS: In prostate cancer patients on ADT older age and lower baseline spine BMD were associated with a greater risk of fracture in untreated patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964492.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Villarreal-Garza C, Villa AR, Perfecto-Arroyo M, García-Aceituno L, Rojas-Flores M, León-Rodríguez E: Knowledge about cancer screening among medical students and residents. J Clin Oncol; 2009 May 20;27(15_suppl):1541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knowledge about cancer screening among medical students and residents.
  • : 1541 Background: Cancer is the second cause of death worldwide.
  • In certain types of cancer, screening may detect the disease in its early stages, increasing survival.
  • We sought to explore the level of knowledge about cancer screening among Mexican medical students and residents.
  • METHODS: A questionnaire-based survey about screening in breast, cervical, colon, and prostate cancer was completed by medical students attending either public or private medical schools, and internal medicine residents from five training centers in Mexico City.
  • Comparing screening knowledge regarding tumor subgroups, residents scored higher than students in relation to tumor markers 65.24 versus 22.82, breast cancer 77.33 versus 69.19, and prostate cancer 75.00 versus 68.53 (p = 0.0001 for the three comparisons); whereas there was no difference in the education concerning cervical and colon cancer screening, 69.44 versus 70.83 (p = 0.518) and 50.61 versus 45.20 (p = 0.114), respectively.
  • CONCLUSIONS: Knowledge of screening guidelines is suboptimal among medical students and residents, especially regarding cervical and colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964082.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Greer J, Temel J, Admane S, Solis J, Lynch T, Pirl W: Code status documentation in the outpatient electronic medical records of patients with metastatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Code status documentation in the outpatient electronic medical records of patients with metastatic cancer.
  • : 9576 Background: Advanced care planning is an essential component of cancer care for patients with incurable malignancies.
  • METHODS: We conducted a retrospective review of outpatient medical records of 2498 patients with metastatic solid tumors seen at an academic cancer center from 10/1/06 through 2/29/08.
  • An electronic database was used to gather information on patient demographics, cancer type, and visits to the cancer center.
  • The sample consisted of patients with metastatic breast, colorectal, non-colorectal gastrointestinal (GI), bladder/kidney, ovarian, prostate, and lung cancers.
  • Code status was documented more frequently in patients with metastatic non-colorectal GI (193/609, 31.7%) and lung (179/583, 30.7%) cancers compared to patients with genitourinary malignancies (bladder/kidney [4/89, 4.5%], ovarian [4/93, 4.3%] and prostate [7/365, 1.9%] cancers).
  • Independent predictors of having documented code status included cancer type and a greater number of visits to the cancer center.
  • Given the importance of advanced care planning for those with terminal illness, interventions are needed to encourage discussion and documentation of end-of-life care preferences in patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Rodriguez Garzotto A, Sepulveda J, Cortijo A, Garcia L, Garcia Rodriguez I, Ciruelos E, Rodriguez Antolin A, Cortes-Funes H, Castellano D: Oral vinorelbine as a fixed-weekly schedule in taxanes-refractory advanced HRPC: A single institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16084

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16084 Background: Vinorelbine (VRL) has been shown to be active in hormone-refractory prostate cancer (HRPC).
  • Oral formulation of VRL represents a significant advance in the treatment of advanced cancer.
  • RESULTS: Thirty seven pts with progressive HR metastatic prostate cancer were evaluated.
  • There were no reported grade 3-4 toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kelly WK, DeBono J, Blumenschein G, Lassen U, Zain J, O'Connor O, Foss F, Tjornelund J, Fagerberg J, Petrylak D: Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major cancer types included colorectal (22%), prostate (17%), bladder (11%).
  • Most frequent related adverse events (AEs), any grade (gr), were fatigue (53%), nausea (49%), anorexia (36%), vomiting (27%), diarrhea (25%).
  • To date, 33 pts (41%) have SD; 5 pts ≥6 months (d on treatment: 710 adenoidcystic, +488 bladder, 485 renal, 196 rectal, 182 prostate), and 12 pts 3-6 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961343.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Deshpande HA, Gettinger S, Rowen E, Abu-Khalaf MM, Clarke J, Burns AJ, Kelly WK: A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nanoparticle albumin-bound paclitaxel (A) has shown greater efficacy and less toxicity than Cremophor-based paclitaxel as a single agent in the treatment of breast cancer.
  • RESULTS: To date 15 pts (2 renal, 3 prostate, 2 bladder, 1 hypopharyngeal, 1 mesothelioma, 1 colorectal, 1 melanoma and 2 leiomyosarcomas) with a median age 51 (range 37 - 78 yrs) have been treated in 3 cohorts.
  • 1 patient (testicular cancer) intended for cohort 1 was a screen failure.
  • Two patients in cohort 3 had grade 3\/4 neutropenia (DLT).
  • Most common severe adverse events were Grade 3 anemia (5%), neutropenia (22%), fatigue (5%) and dehydration (5%).
  • 3 patients had grade 4 neutropenia, 2 in cycle 1 of cohort 3 and 1 in cycle 2 of cohort 2.
  • To date 6 patients had progressive disease, 4 had stable disease (3.8 months), 3 patients (2 with prostate cancer and 1 with hypopharyngeal cancer) had a partial response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961256.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hayes JH, Chen M, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV: Short-course androgen suppression therapy prior to brachytherapy for favorable-risk prostate cancer and the risk of all-cause mortality in men with or without preexisting cardiovascular disease. J Clin Oncol; 2009 May 20;27(15_suppl):5066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-course androgen suppression therapy prior to brachytherapy for favorable-risk prostate cancer and the risk of all-cause mortality in men with or without preexisting cardiovascular disease.
  • : 5066 Background: AST is used to reduce prostate size in men with favorable-risk prostate cancer who have pubic arch interference in order to enable them to undergo prostate brachytherapy.
  • METHODS: The study cohort included 12,792 men with previously-untreated low or intermediate risk prostate cancer (PSA < 20 ng/mL; Gleason score 7 or below on initial biopsy; clinical category T2c or below) treated between 1992 and 2005 at one of 21 community-based medical centers in Illinois, Florida, New York, or North Carolina.
  • Multivariate Cox regression analysis was performed to assess whether significant associations between preexisting CVD and ACM existed adjusting for age, year of treatment and known prostate cancer prognostic factors.
  • CONCLUSIONS: Preexisting CVD is associated with an increased risk of death in men with favorable-risk prostate cancer treated with short-course AST prior to brachytherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964251.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Xu T, Xu Y, Lao R, He K, Xue L, Goldkorn A: Mouse prostate tumor inhibition via disruption of murine telomerase: In vivo and in vitro data for a new preclinical cancer model. J Clin Oncol; 2009 May 20;27(15_suppl):e14631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse prostate tumor inhibition via disruption of murine telomerase: In vivo and in vitro data for a new preclinical cancer model.
  • : e14631 Background: Telomerase-interference (TI), a novel therapeutic strategy, exploits the high telomerase activity in prostate cancer by introducing a mutated telomerase RNA (MT-Ter) that encodes toxic telomeres.
  • We designed and validated 2 new TI gene constructs that specifically target murine telomerase RNA (mTER), enabling the study of TI in preclinical mouse models that are immuno-competent and that develop endogenous prostate tumors.
  • Using a mouse prostate cancer cell line, E4, we tested the 2 constructs for expression (RT-PCR), telomerase activity (TRAP), and biologic activity (53bp1 DNA damage staining, MTS growth assay, TUNEL and caspase apoptosis assays), as well as in vivo efficacy (NOD-SCID allografts).
  • RESULTS: We confirmed MT-mTER expression (∼50-fold) and showed that α-mTer-siRNA specifically depleted WT-mTER (80% reduction) but not MT-mTER when the 2 constructs are co-expressed; thus, the 2 constructs in combination effectively substituted MT-mTer for WT-mTer in the mouse prostate cancer cells.
  • CONCLUSIONS: We successfully designed and validated MT-mTer and α-mTer-siRNA, 2 novel gene constructs that specifically target and co-opt murine telomerase activity within mouse prostate cancer cells.
  • These constructs offer a significant advantage, as they can be used to investigate TI in immuno-competent mice that develop prostate cancer, thereby modeling actual human disease and testing TI-based therapies in a much more informative and authentic manner.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964180.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Nobes JP, Langley SE, Laing RW: Use of metformin and lifestyle intervention to prevent ADT-related metabolic syndrome in prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5159

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of metformin and lifestyle intervention to prevent ADT-related metabolic syndrome in prostate cancer.
  • : 5159 Background: The association between androgen deprivation therapy (ADT) for prostate cancer and metabolic syndrome has been reported, with insulin resistance as the key to its development.
  • METHODS: Forty men with any stage of prostate cancer, due to receive ADT with a GnRH agonist, were recruited to a prospective randomised pilot study.
  • RESULTS: After 6 months a significant reduction in metabolic syndrome cases (NCEP ATP III definition) was seen in the intervention arm (p=0.042), with an equal number seen in the control arm as at baseline.
  • CONCLUSIONS: ADT is widely used in prostate cancer, but metabolic complications may be responsible for an increased cardiovascular mortality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964471.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Hoffman KE, D'Amico AV: Prostate cancer screening practice among men age 75 and older: Results from a national survey. J Clin Oncol; 2009 May 20;27(15_suppl):e16034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer screening practice among men age 75 and older: Results from a national survey.
  • Preventative Services Task Force recently recommended not to screen men aged 75 and older for prostate cancer.
  • This study evaluated the use of prostate specific antigen (PSA) screening among men age 75 and older prior to this declaration.
  • METHODS: The study cohort comprised 718 men age 75 or older without a history of prostate cancer who responded to the 2005 National Health Interview Survey, representing an estimated 4.47 million non-institutionalized men annually.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962959.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Feyerabend S, Stefanovic S, Gouttefangeas C, Widenmeyer M, Wernet D, Hennenlotter J, Bedke J, Dietz K, Pascolo S, Rammensee H, Stenzl A: HLA-associated multipeptide vaccination in biochemically relapsed prostate cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):5134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-associated multipeptide vaccination in biochemically relapsed prostate cancer patients.
  • : 5134 Background: We conduct a phase I/II monocenter clinical trial using multi peptide vaccination in patients with hormone naive, biochemically relapsed prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964428.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Alaoui-Jamali MA Sr, Gupta A, Szarek WA, Bismar TA, Gheorghe R, Schipper HM: A novel selective therapeutic targeting heme oxygenase-1 revealed a potent antimetastatic activity in androgen-refractory human prostate cancer models. J Clin Oncol; 2009 May 20;27(15_suppl):e16090

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel selective therapeutic targeting heme oxygenase-1 revealed a potent antimetastatic activity in androgen-refractory human prostate cancer models.
  • : e16090 Prostate cancer is a highly prevalent disease.
  • Despite a significant improvement in the overall survival attributed in part to early detection and introduction of novel therapeutic modalities, many cancer patients at primary diagnosis present advanced disease or experience recurrence of the cancer.
  • The progression of prostate cancer (PCA) to hormone-refractory phenotype (HRPCA) and to metastasis is an ominous event in patients with advanced PCA.
  • In this study, we identified heme oxygenase 1 (HO-1) to be significantly upregulated in epithelial PCA cells, but not in surrounding stromal cells, from hormone refractory prostate cancer cases compared to hormone-responsive prostate cancer and to benign tissues.
  • Specifically, inhibition of HO-1 gene in androgen-independent and highly invasive prostate cancer cells, PC3M, decreased HO-1 activity, oxidative stress, MAPKs activation, cell proliferation, and cell migration and invasion in vitro, as well as inhibition of prostate tumor growth and lymph nodes and lung metastases in vivo.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963085.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. von Boehmer L, Wild P, Keller L, Hermanns T, Provenzano M, Sais G, Jaeger E, Stenner F, Moch H, Knuth A: Cancer testis antigen expression and immune responses by prostate cancer patients: Implications for prognosis and immunotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer testis antigen expression and immune responses by prostate cancer patients: Implications for prognosis and immunotherapy.
  • : e16101 Background: Prostate cancer (PC) is the most frequent malignancy in men and it continues to be one of the most common fatal cancers.
  • Treatment options in advanced castration-resistant prostate cancer (CRPC) are limited.
  • Cancer testis (CT) antigens are expressed in a variety of human cancers, but not in normal tissues except for MHC deficient spermatogonia, and represent promising targets for immunotherapy.
  • The aim of this study was to investigate which CT antigens are expressed and immunogenic and hence represent promising targets for patients with prostate cancer and correlate these findings with clinicopathological characteristics.
  • METHODS: To determine the expression of 6 CT antigens in prostate cancer immunohistochemistry was performed on tissue micro arrays.
  • We investigated 6 CT antigens (NY-ESO.1, MAGE-C1, MAGE-C2, GAGE, MAGE-A1 and MAGE-A4) in benign hyperplasia (n=45), early (n=388) and late stage (n=71) prostate cancer.
  • To determine the occurrence of spontaneous antibodies against cancer testis antigens, ELISA and Western blot was performed for NY-ESO-1, MAGE-C1 and MAGE-C2 with sera from prostate cancer patients.
  • RESULTS: CT antigens are increasingly expressed in late stage prostate cancers.
  • In later stage metastatic prostate cancer patients NY-ESO-1 is more often expressed, inducing NY-ESO-1 specific antibodies.
  • CONCLUSIONS: Cancer testis (CT) antigens are prognostic markers, frequently inducing immune responses and may be suitable for immunotherapeutic intervention in patients with prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963349.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Elshaikh MA, Abdel Hafeez Z, Lu M, Ibrahim D, El Masry T, Yousef A: The effect of androgen deprivation therapy on CD4/CD8 T cells in HIV-negative patients receiving definitive 3D radiation treatment for their prostate carcinoma: Final report of a prospective study. J Clin Oncol; 2009 May 20;27(15_suppl):11056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of androgen deprivation therapy on CD4/CD8 T cells in HIV-negative patients receiving definitive 3D radiation treatment for their prostate carcinoma: Final report of a prospective study.
  • The aim of this prospective study is to explore the correlation of the absolute CD4/CD8 T cell counts and total testosterone in patients receiving androgen deprivation therapy (ADT) with goserelin acetate and definitive radiation treatment (RT) for their prostate cancer.
  • All patients received 6 months of ADT prior to (baseline) and during RT to the prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963161.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Brodowicz T, Steiner I, Beslija S, Ciuleanu TE, Inbar M, Krzakowski M, Kahan Z, Tzekova V, Vrbanec D, Zielinski CC: Time interval between final protocol approval (FPA) and inclusion of the first patient into randomized clinical trials (RCTs) performed by the Central European Cooperative Oncology Group (CECOG): A 10-year experience. J Clin Oncol; 2009 May 20;27(15_suppl):6546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the European legislation passed in 2001 (Directive 2001/20/EC), clinical trials must get ethical approval and approval from the competent authorities (CA).
  • METHODS: Within the last 10 years, CECOG conducted trials in breast, colorectal, esophago-gastric, NSCLC, pancreatic, prostate cancer and GIST.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964062.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Martinelli F, Quinten C, Coens C, Flechtner H, Gotay C, Mendoza T, Osoba D, Reeve B, Wang X, Bottomley A: Relationships among health-related quality of life indicators in cancer patients: A pooled study of baseline EORTC QLQ-C30 data from 6,739 patients. J Clin Oncol; 2009 May 20;27(15_suppl):9612

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationships among health-related quality of life indicators in cancer patients: A pooled study of baseline EORTC QLQ-C30 data from 6,739 patients.
  • : 9612 Background: Cancer patients frequently experience multiple and co-occuring problems due to their illness and therapies.
  • The objective of this meta-analysis was to identify how HRQoL indicators cluster among cancer patients.
  • METHODS: Retrospective pooling of 29 European Organisation for Research and Treatment of Cancer (EORTC) randomized clinical trials, among 10 cancer sites, yielded baseline EORTC QLQ-C30 HRQoL data for a total of 6739 patients.
  • Dendrograms of the HRQoL indicators were plotted for the overall data and for each cancer site.
  • The gastrointestinal cluster was reproduced in all 10 cancer sites.
  • We found that pain was not correlated with the other variables of the physical function cluster for patients with brain, colorectal or pancreatic cancer.
  • For the psychological component cluster, cognitive functioning was not correlated with the other variables of the cluster for breast or pancreatic cancer patients, while insomnia was found not to be correlated with the other variables of the cluster for prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963865.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Ang J, Mikropoulos C, Stavridi F, Rudman S, Uttenreuther-Fisher M, Shahidi M, Pemberton K, Wind S, de Bono J, Spicer JF: A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel. J Clin Oncol; 2009 May 20;27(15_suppl):e14541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Partial responses were seen in patients with non-small cell lung cancer (3), prostate cancer (1), oesophageal cancer (1) and cholangiocarcinoma (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963619.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Poveda A, Kaye SB, McCormack RT, Wang S, Ricci D, Broderick E, Parekh T, Lebedinsky C, Tecero JC, Monk BJ: Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD. J Clin Oncol; 2009 May 20;27(15_suppl):5551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD.
  • : 5551 Background: Circulating tumor cells (CTC) have demonstrated predictive and prognostic value among patients with metastatic breast, colorectal, and prostate cancer.
  • In a phase III study of pegylated liposomal doxorubicin (PLD) with trabectedin (T) vs PLD for relapsed ovarian cancer, we assessed the affect of CTCs on progression free survival, (PFS) and overall survival (OS).
  • Multivariate analyses that include baseline CTC, baseline CA125, platinum sensitivity status, largest diameter lesion, number of tumor lesions, ECOG PS, age, tumor histology, tumor grade and prior taxane show that patients with elevated baseline CTC have 1.58 (p = 0.058) and 1.54 (p = 0.096) fold higher risk for progression and death respectively.
  • CONCLUSIONS: Results from this study indicate that although CTC detection in blood from relapsed recurrent ovarian cancer patients is relatively low, elevated numbers of CTCs imparts an unfavorable prognosis for patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962543.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Gandhi M, Calahan C, Oishi K, Lacouture M: Unexpected dermatologic toxicities from anticancer therapies: Survivors' perspectives. J Clin Oncol; 2009 May 20;27(15_suppl):e20673

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20673 Background: As oncologic therapies have shown improved survival, there is a growing attention to other aspects of the cancer experience from the survivors' perspectives.
  • METHODS: CancerCare, a national nonprofit organization, mailed 1,369 surveys to cancer survivors completing their treatment.
  • Of those 379, 250 (66%) were diagnosed with breast cancer.
  • The remaining 127 (33%) had ovarian, lung, colorectal, prostate, bladder, kidney, or other malignancy.
  • CONCLUSIONS: Dermatologic toxicities are least anticipated by the cancer patients prior to their treatments, when compared to gastrointestinal and constitutional events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961687.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Rosen L, Gordon MS, Hurwitz HI, Wong MK, Adams BJ, Alvarez D, Seon BK, Leigh BR, Theuer CP: Early evidence of tolerability and clinical activity from a phase I study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3518

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early evidence of tolerability and clinical activity from a phase I study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer.
  • METHODS: The safety and PK of TRC105 were evaluated in patients with refractory cancer.
  • One patient experienced dose-limiting toxicity (DLT) at 0.1 mg/kg of grade 4 gastric ulcer bleeding on Day 4 which resolved spontaneously.
  • No other grade 3 or 4 adverse events were reported.
  • Possibly related grade 1-2 adverse events were rare including fatigue, anemia, proteinuria, dysgeusia, diarrhea, flushing, hyperuricemia and intermittent postcoital vaginal bleeding.
  • One patient with castrate-refractory prostate cancer remains on study after 13 months of TRC105 at 0.01 mg/kg with a complete PSA response and bone scan normalization.
  • In addition, 6-month stable disease was seen in a patient with ovarian cancer (CA125 decrease of 16%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961300.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Pinthus JH, Farrokhyar F, Hassouna MM, Woods E, Orovan WL: Two-years biochemical failure-free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: Prospective single center study of 196 patients. J Clin Oncol; 2009 May 20;27(15_suppl):5117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-years biochemical failure-free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: Prospective single center study of 196 patients.
  • : 5117 Background: HIFU is an emerging ablative modality for the treatment of localized prostate cancer with limited reports on oncological outcome.
  • Biopsy Gleason scores at diagnosis (median 9 cores) were 5, 6, 3+4, 4+3 in 1, 91, 66 and 38 patients, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964388.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Renzulli JF 2nd, Dooner G, Owens C, Colvin G, Dooner M, Del Tatto M, Goldstein L, Quesenberry P: Microvesicular-mediated gene transfer of prostate tumor markers. J Clin Oncol; 2009 May 20;27(15_suppl):e16076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvesicular-mediated gene transfer of prostate tumor markers.
  • Recent work has focused on the potential for cancer vaccines via microvesicles.
  • Our objective is to determine whether there is transfer of genetic or transcriptional factors via microvesicles from human prostate cancer cells to fresh human marrow cells.
  • METHODS: Fresh prostate tissue was harvested from surgical specimens following radical retropubic prostatectomy.
  • Samples were histologically confirmed to contain prostatic adenocarcinoma.
  • Co-cultures were established using a transwell system in which 0.05-0.100 grams of prostate tissue was minced and co-cultured with 1-3 million normal, human donor marrow cells for 2-7 days.
  • Target cells were collected and total RNA was analyzed for prostate-specific gene expression byReal Time RT-PCR.
  • RESULTS: We have observed significant increases in gene expression in marrow cells co-cultured with prostate tumor cells (Gleason grades 6-9).
  • CONCLUSIONS: These studies demonstrate that prostate specific genes are present in fresh human marrow cells after co-culture with tumor tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963050.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Wang S, Jiang F, Bai L, Long JJ, Qiu S, Chen J, McEachern D: Effect of (-)-gossypol (AT-101) on transcriptional regulation of Noxa and Puma and on Mcl-1-mediated cancer cell resistance to apoptosis. J Clin Oncol; 2009 May 20;27(15_suppl):e14611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of (-)-gossypol (AT-101) on transcriptional regulation of Noxa and Puma and on Mcl-1-mediated cancer cell resistance to apoptosis.
  • In this study, we have performed detailed investigations using a panel of human cancer cell lines on the mechanism of action for AT-101.
  • METHODS: A series of human breast and prostate cancer cell lines were utilized to evaluate the antitumor activity of AT-101.
  • RESULTS: AT-101 induced apoptosis in both Bax/Bak-dependent and -independent manners in a variety of human cancer cell lines concomitant with increased expression of Noxa and Puma in a p53-independent manner.
  • Furthermore, AT-101 effectively overcame Mcl-1-mediated cancer cell resistance to apoptosis.
  • CONCLUSIONS: Our findings suggest that transcriptional up-regulation of pro-apoptotic Noxa and Puma contributes to the antitumor activity of AT-101, which plays a dominant role in antagonizing Mcl-1 and overcoming Mcl-1-mediated resistance to apoptosis of cancer cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964122.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Stevenson MM, Mostertz W, Acharya C, Walters K, Barry W, Tuchman S, Ready N, Onaitis M, Crawford J, Potti A: Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):11001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
  • : 11001 Background: Cancer cells possess traits reminiscent of those ascribed to normal stem cells.
  • It is unclear whether these phenotypic similarities between normal/embryonic stem cells and mature tumor cells, specific to lung cancer, are a result of underlying biologic processes, such as specific molecular pathways and regulatory networks.
  • METHODS: Using a large cohort of lung cancer cell lines with associated gene expression data, genes associated with an embryonic stem cell identity were used to develop a 'signature' representative of embryonic stemness (ES) activity specific to lung adenocarcinoma.
  • The ES signature was applied to three independent early (stage I - IIIa) lung adenocarcinoma data sets (N = 634) with clinically annotated gene expression data.
  • RESULTS: Using Bayesian regression analysis, a 100 gene signature representative of ES activity in lung adenocarcinoma was developed and validated in a leave-one-out-analysis.
  • GSEA identified gene sets significantly represented in the ES signature: signature of neoplastic transformation, signature of undifferentiated cancer, BRCA pathway, and fibroblast serum response pathway, all associated with cancer invasiveness.
  • The ES signature was not prognostic in prostate, ovarian, or breast adenocarcinomas.
  • Lung tumors (N=634) and adenocarcinoma cell lines (N=31) with ES were more resistant to cisplatin (p<0.0001 and p=0.0063, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Di Segni S, Sperduti I, Cinquina A, Contestabile M, Nuvoli B, Giannarelli D, Cognetti F, Gelibter AJ: Analysis of phase I pharmacokinetic studies with targeted molecules based on gender and age. J Clin Oncol; 2009 May 20;27(15_suppl):2521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We excluded trials involving Radiation therapy alone, Hematological malignancies, and trials of Gender related pathology (ovarian, prostate and breast cancer).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961844.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Lee B, Franklin I, Coombes C, Leonard R, Gishen P, Stebbing J: The efficacy of percutaneous vertebroplasty for palliation of pain in vertebral metastases associated with solid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):e20670

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: From 136 cases that underwent percutaneous vertebroplasties, 19 were performed mainly in breast, prostate, lung, and renal cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961694.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Hauke RJ, Enke C: Phase I study of extended field intensity modulated radiation therapy (EF-IMRT) and docetaxel in patients with node-positive prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16154

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of extended field intensity modulated radiation therapy (EF-IMRT) and docetaxel in patients with node-positive prostate cancer.
  • : e16154 Background: Treatment for patients with node positive prostate cancer remains challenging.
  • We conducted a phase I study combining HAT with EF-IMRT and concurrent docetaxel in men with biopsy-proven node positive prostate cancer.
  • EF-IMRT target doses: prostate 81.0 Gy/45 fractions; intraprostatic target 81.0 - 84.6 Gy/45 fractions; pathologically involved lymph node 72 Gy/43 fractions; pelvic lymph nodes 54.0 Gy to 70.2 Gy/43 fractions.
  • Ultrasound targeting and a water filled rectal catheter balloon were used daily to minimize movement and locate the prostate.
  • The primary endpoint was determining grade III/IV toxicity.
  • No grade III/IV toxicities occurred within the defined observation period.
  • Seven of 9 patients are now beyond the 2 year post-radiation period; 4 patients remain in remission; one patient developed primary lung cancer; another was lost to follow up at 1 year post-radiation and 3 had relapsed disease within the 2 year post-radiation window.
  • CONCLUSIONS: The addition of weekly docetaxel to EF-IMRT along with HAT is well tolerated in patients with node positive prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963414.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Mitsiades N, Schultz N, Taylor BS, Hieronymus H, Satagopan J, Scardino PT, Reuter VE, Sander C, Sawyers C, Scher HI, Prostate Cancer Genome Project Group: Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies. J Clin Oncol; 2009 May 20;27(15_suppl):5002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies.
  • : 5002 Background: Androgen receptor (AR) signaling remains active in castration-resistant prostate cancer (CRPC) despite castrate levels of circulating androgens.
  • This is indicated by continuous expression of androgen-responsive genes and is due to mechanisms that include: increased AR expression; AR mutations allowing promiscuous activation by alternative ligands; and increased intratumoral androgen levels, resulting from in situ steroidogenesis.
  • METHODS: Gene expression profiles of 30 normal prostate tissue samples, 131 primary prostate carcinomas (PCas) and 16 metastatic PCas, generated using Affymetrix Exon arrays, were interrogated for levels of 40 mRNAs encoding AR, SHBG, 28 enzymes involved in androgen synthesis and 10 enzymes involved in androgen inactivation.
  • RESULTS: Metastatic PCas expressed higher average transcript levels for AR and several steroidogenic enzymes, including SRD5A1 and SRD5A3, than primary PCas and normal prostate tissue.
  • Expression of SRD5A2, CYP3A4, CYP3A5, and CYP3A7 mRNAs was decreased both in primary and metastatic tumors compared to normal prostate tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Turner JS, Chen CS, Butler W, Bearden J 3rd, Garrett-Mayer E, Onicescu G, Kraft AS: Bortezomib therapy for prostate specific antigen (PSA)-only relapse after definitive local therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib therapy for prostate specific antigen (PSA)-only relapse after definitive local therapy.
  • : e16053 Background: We conducted a single arm, phase II trial of single-agent bortezomib, a proteasome inhibitor, in patients with prostate cancer with biochemical recurrence (PSA relapse) after definitive local therapy.
  • 3 of 13 patients (23%) achieved complete responses and 1 a partial response (PR) for a response rate of 30% (95% CI: 0.09 -0.61).
  • The major toxicity associated with bortezomib therapy was peripheral neuropathy (7 pts, grade 3 in 3 pts) requiring dose reductions in 3 cases and discontinuation of therapy in 4 patients.
  • Other toxicities included non-neutropenic infections (shingles in 2 pts), 1 small bowel ileus (grade 3), and 1 case of thrombocytopenia (grade 3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963004.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Schaly B, Osei EK, Barnett R: Poster - Thurs Eve-27: Method of estimating imaging dose to patients from on-line cone-beam computed tomography using patient size data. Med Phys; 2008 Jul;35(7Part2):3406

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At our institution, we use Varian's On Board Imager® (OBI) mainly for imaging prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512838.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computed tomography / Cone beam computed tomography / Dosimetry / Field size / Ionization chambers / Medical imaging / Radiation therapy / Thermoluminescence / Thermoluminescent dosimeters
  •  go-up   go-down


49. Epenetos AA, Kousparou C, Stylianou S: Inhibition of Notch and tumor regression. J Clin Oncol; 2009 May 20;27(15_suppl):e14623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is increasing evidence that the same molecular pathways regulating the self renewal of stem cells are also being employed in cancer progression.
  • Increasing evidence suggests that the Notch signaling pathway is frequently up regulated in many forms of cancer including acute T-cell lymphoblastic leukemia, cervical, prostate, lung, breast and others.
  • Thus,inhibition of the pathway could provide a novel treatment of cancer and cancer stem cells.
  • CONCLUSIONS: The TR4 protein, a Notch inhibitor, can induce tumor regression and resolution of breast and colon cancer xenografts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964214.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Lu L, Schafer P, Bartlett JB: Inhibition by lenalidomide of growth factor and hypoxia-induced signaling in endothelial and epithelial tumor cells, and effects within the tumor cell microenvironment. J Clin Oncol; 2009 May 20;27(15_suppl):e14620

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lysophosphatidic acid (LPA) is a key pro-survival factor present at high levels within the ascites of ovarian cancer patients which confers increased tumor invasiveness and reduced survival.
  • METHODS: The effect of lenalidomide on growth factor-induced Akt phosphorylation was investigated in endothelial cells, NHL cells, and ovarian cancer cells in vitro.
  • Ovarian cancer cell lines SKOV-3 and OVCAR-3 were treated with LPA and the effect of lenalidomide on invasiveness via enhanced p-Akt was investigated.
  • Lenalidomide inhibited hypoxia-induced HIF-1α expression by endothelial cells and by epithelial tumor cells, including prostate, breast, pancreatic, renal and ovarian tumor cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964203.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Zhu Y, Chen L: Identification and characterization of SP cells in human lung adenocarcinoma SPC-A1 cells. J Clin Oncol; 2009 May 20;27(15_suppl):e22230

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of SP cells in human lung adenocarcinoma SPC-A1 cells.
  • With an extensive understanding of their biology, a major role for stem cells in the malignant process has been proposed and the existence of cancer stem cells(CSCs) has been confirmed in hematopoietic malignancies, brain cancer, and solid organ malignancies including breast, prostate, colon, and pancreatic cancer.
  • Lung cancer is the leading cause of cancer mortality in most large cities of China.
  • It is possible that lung cancer contains cancer stem cells responsible for its malignancy.
  • The aim of this study is to identify, characterize and enrich the CSC population that drives and maintains lung adenocarcinoma growth and metastasis.
  • METHODS: Side population (SP) cell analysis and sorting were applied to established human lung adenocarcinoma cell line and an attempt to further enrich them by preliminary serum-free culture before fluorescence activated cell sorting(FACS) was done.
  • RESULTS: Lung cancer cells could grow in a serum-free Medium (SFM) as non-adherent spheres similar to neurospheres or mammospheres.
  • Flow cytometric analysis of cell phenotyping showed that SP cells expressed CD133 and CD44, the common cell surface markers of cancer stem cells, while non-SP cells only expressed CD44.
  • CONCLUSIONS: SP cells existed in human lung adenocarcinoma cell lines and they could be further enriched by preliminary serum-free culture before FACS sorting.
  • SP cells possessed the properties of cancer stem cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Abdah-Bortnyak RV, Haick H, Billan S, Peng G, Trock E, Shachada N, Kuten A: Sniffing out cancer from real breath samples by means of nanomaterial-based electronic nose device. J Clin Oncol; 2009 May 20;27(15_suppl):e17552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sniffing out cancer from real breath samples by means of nanomaterial-based electronic nose device.
  • : e17552 Background: Several studies have shown that characteristic patterns of volatile organic compounds (VOCs) appear to be elevated in the alveolar breath of cancer patients, as compared to healthy controls.
  • It has been shown, that VOCs' composition acts as a fingerprint for the distinction of a certain cancer from other cancers, including the cases where various cancers have similar type of biomarkers.
  • The goal of the current study is to establish a background to ultimately achieve a simple-to-use device that can detect such patterns of cancer when exhaling into it.
  • (II) 30 patients with lung cancer;.
  • (III) 15 patients with breast cancer;.
  • (IV) 20 patients with colon cancer;.
  • (V) 5 patients with prostate cancer; and (VI) 5 patients with head and neck cancer.
  • The breath of the volunteers was examined by means of gas chromatography linked with mass spectrometry technique (GC-MS) as well as by an electronic nose device that is based on molecularly modified Au nanoparticles to check the feasibility of the electronic nose in cancer detection via breath samples Results: GC-MS results showed that each category of cancer has a unique pattern (or mixture) of VOCs.
  • In parallel to these findings, results indicate the ability of nanomaterial-based electronic nose devices to differentiate between "healthy" and "cancerous" breath, and, furthermore, between the breath of patients with different cancer types, with >92% sensitivity.
  • CONCLUSIONS: The electronic nose technology has a high potential for assessing various types of cancer via simple exhalation procedure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963875.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Pandurengan RK, Strom SS, Trent J 2nd: Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients. J Clin Oncol; 2009 May 20;27(15_suppl):10567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anderson Cancer Center from 1995 to 2007.
  • Multiple primaries included tumors that were not considered to be a metastasis, invasion or recurrence of GIST excluding non-melanoma skin cancer.
  • Data on gender, age at diagnosis of cancer, follow-up time after diagnosis, and death rate were collected.
  • Median age at diagnosis of GIST was 57 for patients with GIST only whereas it was 68 in patients with GIST+.
  • The total numbers of other primaries developed before the diagnosis of GIST was higher (134) than the primaries developed after the diagnosis of GIST (53).
  • The most frequent primaries observed before the diagnosis of GIST were prostate (25), breast (12), esophagus (9), kidney (7) and melanoma (6).
  • Lung (5) and kidney (5) were the most frequent type of primaries that developed after the diagnosis of GIST.
  • The 5-yr survival was 68% for patients with GIST+ when the other primary occurred before GIST, 61% for patients with GIST+ when the other primary occurred after the diagnosis of GIST, 58% for patients with GIST only, and 49% for GIST++ patients with two or more other primaries (p=0.002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963788.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Sloan JA, Liu H, Sargent DJ, Satele D, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Loprinzi CL, Buckner JC: A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):9599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials.
  • The effect sizes were consistent across different disease sites (GI, esophageal, head and neck, prostate, lung, breast and others).
  • Single-item measures of overall QOL and fatigue can help to identify vulnerable subpopulations among cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Hauser KA, Karafa M, Seyidova-Khoshknabi D, Davis MP, Walsh D: Prevalence and risk factors of vitamin D insufficiency in cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and risk factors of vitamin D insufficiency in cancer.
  • : 9581 Background: Low vitamin D has been linked to increased cancer incidence and reduced prognosis.
  • Little is known about prevalence and risks of insufficiency in cancer.
  • Data extracted: demographics (age, gender, race), cancer site (primary and metastatic, ICD-9 codes) and first 25 hydroxy vitamin D level [25OHD] during the study period.
  • Most common cancers: breast (19%), prostate (18%), skin (13%).
  • They were more likely female (66% vs 47%), and to have breast, hepatobiliary, skin or thyroid cancer, than those not tested (both p<0.001).
  • Insufficiency was associated with male gender, race (African American), month of test (Feb-Apr, Oct), cancer type (hepatobiliary, genitourinary, pancreas, upper gastrointestinal), metastatic disease, low albumin, high bilirubin and AST, and lack of antineoplastic or vitamin D medication (all p<0.01).
  • Multivariable predictors were cancer type, test month, African American race, low albumin, and lack of antineoplastic or vitamin D medication (all p<0.01).
  • CONCLUSIONS: Vitamin D insufficiency is highly prevalent among cancer patients tested.
  • This study is limited by selection bias but indicates need for prospective vitamin D evaluation in cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963701.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. McDowell GC 2nd, Mitchell JW, Moore TD: The use of intrathecal ziconotide to manage refractory malignant pain: Five case studies. J Clin Oncol; 2009 May 20;27(15_suppl):e20737

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Four women (aged 27, 31, 46, and 68 years) with metastatic breast cancer and a 61-year-old man with metastatic prostate cancer were intolerant of or experienced inadequate analgesia with systemic analgesics and/or IT opioids with or without clonidine or bupivacaine.
  • Although the 46-year-old woman experienced substantial pain relief (55.6% reduction in NPI score) and quality of life improvement during ∼3 months of ziconotide therapy, she died of cancer complications that were unrelated to ziconotide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Patnaik A, Chiorean EG, Tolcher A, Papadopoulos K, Beeram M, Kee D, Waddell M, Gilles E, Buchbinder A: EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):2564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types included colorectal cancer (7 pts); renal cancer (4 pts); soft-tissue sarcoma (STS; 2 pts); angiosarcoma (1 pt); melanoma (1 pt); and breast, ovarian, pancreatic, and prostate cancers (1 pt each).
  • Most Aes were Grade 1 or 2.
  • Stable disease was observed for 1 pt with angiosarcoma (28 wks) and 1 pt with renal cancer (12 wks).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Hertz P, Seruga B, Le LW, Tannock IF: Global drug development in cancer: A cross-sectional study of clinical trial registries. J Clin Oncol; 2009 May 20;27(15_suppl):2520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global drug development in cancer: A cross-sectional study of clinical trial registries.
  • METHODS: We determined characteristics of phase II and III clinical trials evaluating new drugs in oncology, which were registered with WHO International Clinical Trial Registries between 01/2008 and 06/2008.
  • Simple correlation analysis was performed between the number of clinical trials and incidence, mortality and prevalence per cancer site after log transformation of variables.
  • Most trials (and most phase III trials) evaluated treatments for globally prevalent cancers: breast, lung, prostate, and colorectal cancer (Table).
  • Prevalence of a particular cancer type in both the MDW and LDW correlated significantly with the number of clinical trials (Pearson r = 0.63 and 0.55; p = 0.01 and 0.03, respectively).
  • CONCLUSIONS: Global drug development in cancer predominates in globally prevalent cancers, which are a more important cause of mortality in the MDW than in the LDW.
  • Cancer sites that are major killers globally, and especially in the LDW (e.g., stomach, liver, and esophageal cancer) should receive priority for clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961846.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Sarker D, Kristeleit R, Mazina KE, Ware JA, Yan Y, Dresser M, Derynck MK, De-Bono J: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol; 2009 May 20;27(15_suppl):3538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GDC-0941 is a potent and selective oral inhibitor of class I PI3K and demonstrates activity in a broad range of preclinical models (breast, ovarian, lung, and prostate).
  • GDC-0941 was generally well-tolerated with no drug related Grade 3 or 4 AEs or DLTs to date.
  • Grade 1 diarrhea, nausea, dysgeusia, peripheral sensory neuropathy, dry mouth, thrombocytopenia, and increased aspartate aminotransferase have been observed.
  • GDC-0941 effects on FDG-PET imaging is being assessed, with 1 patient with HER2+ metastatic breast cancer showing a reduction in FDG uptake and improvement of a chest wall lesion (dose level 60 mg qd).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961334.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Coens C, Martinelli F, Quinten C, Cleeland CS, Greimel E, King M, Ringash J, Schmucker-Von Koch J, Shi Q, Bottomley A: Health-related quality of life indicators and overall quality of life: Results from a cluster analysis on baseline EORTC QLQ-C30 data from 6,739 cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life indicators and overall quality of life: Results from a cluster analysis on baseline EORTC QLQ-C30 data from 6,739 cancer patients.
  • : e20576 Background: Increasingly randomized controlled trials in cancer research include Health-related Quality of Life (HRQoL) alongside traditional biomedical outcome measures.
  • The majority of these trials focus on a general cancer HRQoL measure.
  • METHODS: Retrospective pooling of 29 European Organisation for Research and Treatment of Cancer (EORTC) clinical trials, among 10 cancer sites, yielded baseline EORTC QLQ-C30 data for a total of 6,739 patients.
  • A cluster analysis, using Ward's method, was performed to determine how the 15 HRQoL indicators, and the Global Health scale (GH) in particular, cluster overall and by cancer characteristics.
  • Dendrograms of the HRQoL indicators were plotted for each cancer type.
  • When looking across the 10 different cancer sites, the GH scale was mainly linked with a physical component in brain, head and neck, lung, melanoma, ovarian, pancreatic and prostate cancer.
  • However, in breast and testicular cancer, GH was more strongly associated with the emotional scales.
  • This result is consistent across stage of disease and most cancer sites.
  • The different results seen in patients with breast and testicular cancer deserve additional investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961104.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Pandey R, Dey S, Mukhopadhyay A: The better bisphosphonate in patients with bone metastasis: Zoledronic acid or ibandronic acid? A study from Eastern India. J Clin Oncol; 2009 May 20;27(15_suppl):e20524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients in both the arms were well matched for their diagnosis, stage of disease, burden of skeletal disease and performance status.
  • Different diagnoses were, carcinoma breast (n=99), carcinoma prostate (n=54), myeloma (n=48), carcinoma lung (n=23), others (n=20).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961007.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Krupski TL, Mouraviev V, Mayes J, Polascik T: Psychosocial impact of prostate cancer surgery on sexual intimacy. J Clin Oncol; 2009 May 20;27(15_suppl):e20685

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychosocial impact of prostate cancer surgery on sexual intimacy.
  • : e20685 Background: Prostate cancer survivors live with the day-to-day consequences of the disease and its treatment.
  • Prostate cancer, has been labeled a "relationship disease" because it impacts both partners.
  • We designed a retrospective survey asking patients' and their partners' about the physiologic and psychosocial changes experienced after prostate cancer treatment.
  • METHODS: The study design is a cross sectional retrospective mailing sent to men treated surgically for prostate cancer.
  • In terms of emotional status, 20% were diagnosed with depression and 10% with anxiety since their prostate cancer diagnosis and of those 32% felt it affected their sexual status.
  • CONCLUSIONS: These preliminary findings suggest that prostate cancer treatment may be associated with psychosocial problems related to depression, anxiety, and self- esteem that impact sexual relationships.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961787.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Granberg C, Thompson RH, Quevedo JF, Karnes RJ, Frank I, Kwon ED, Blute ML: Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy. J Clin Oncol; 2009 May 20;27(15_suppl):e16103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy.
  • : e16103 Background: At present, androgen ablation (AA) therapy ± radiation therapy represents a first-line treatment for patients with unresectable locally advanced prostate cancer (CAP), typically resulting in palliative disease control.
  • These two patients presented with 80% of biopsies involved with cancer, extraprostatic extension, seminal vesicle (SV) invasion, and bladder base involvement.
  • On final pathology, both exhibited extensive treatment effect, remission of SV involvement, and robust disaggregation of solid tumors resulting in only microscopic, non-contiguous foci of residual intraprostatic cancer.
  • CONCLUSIONS: We have been able to demonstrate true down-staging of locally advanced prostate cancer with neoadjuvant AA + MDX-010 therapy.
  • This therapeutic modality exhibits significant promise for men with unresectable disease and may provide durable and potentially curative cancer control.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963333.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ: Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol; 2009 May 20;27(15_suppl):5061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086).
  • : 5061 Background: Dasatinib, a potent inhibitor of SRC family kinases, inhibits in vitro prostate cancer cell proliferation and migration.
  • We report promising preliminary results of dasatinib in combination with docetaxel (D) for treatment of metastatic castration-resistant prostate cancer (CRPC).
  • PSA response was seen in 13/32 (41%) pts, clinical benefit (PR + SD) for RECIST-evaluable pts was 21/21, [7 PR, 5 uPR and 4 SD (at ≥21 wks) and 5 SD at ≥6 wk)].
  • 6 of 42 pts experienced ≥ grade 3 adverse events (AEs), including fatigue, myelosuppression and pleural effusion (n = 1).
  • Most common grade 1/2 AEs were fatigue, dysgeusia, GI, and skin disorders.
  • These data confirm the antitumor and antiosteoclast activity of dasatinib in combination with D and serve as the basis for the ongoing phase III study of this combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962978.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Kasimis B, Chang V, Gounder S, Gonzalez M, Finch-Cruz C, Blumenfrucht M, Srinivas S, Cogswell J, Morales E, Ahmed S: Prediction of survival by immunohistochemical stains (IHC) in stage D2 prostate cancer patients (pts): The importance of pTEN overexpression. J Clin Oncol; 2009 May 20;27(15_suppl):e16019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of survival by immunohistochemical stains (IHC) in stage D2 prostate cancer patients (pts): The importance of pTEN overexpression.
  • : e16019 Background: Several signal transduction pathways,important for apoptosis and angiogenesis were idendified and their expression and correlation with survival was studied by IHC in archival prostate cancer biopsies.
  • METHODS: In an IRB approved study,42 pts had adequate tissue preserved between 1992 and 2006 and their charts were reviewed retrospectively.IHC stains to detect tumor expression of S6(ribosomal),p70s6,pTEN,AKT-1,BCL-1(Cyclin D1),VEGF,c-KIT,PDGFR-alpha and PDGFR-beta were performed by US Labs(Irvine,CA).All results were independently evaluated by two pathologists.Immunoreactivity was scored using a semiquantitative system combining intensity of staining(0-3+) and percentage of cells staining positive(0-3+).The total score was obtained by adding the scores for indensity and the percentage of positive cells,then averaging the resuts obtained by each reader.For the purpose of this study, stain intensity of 0-1+ was considered negative and the intensity of 2-3+ was considered positive.A Cox regression survival model for each stain was developed with variables known to predict survival :Gleason score,Hemoglobin(Hgb),Alkaline Phosphatase(Alk Phos),Prostate Specific Antigen(PSA),Lactate Dehydrogenase(LDH) levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962908.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Chibani O, Williamson JF: MCPI©: A sub-minute Monte Carlo dose calculation engine for prostate implants. Med Phys; 2005 Dec;32(12):3688-3698

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MCPI©: A sub-minute Monte Carlo dose calculation engine for prostate implants.
  • An accelerated Monte Carlo code [Monte Carlo dose calculation for prostate implant (MCPI)] is developed for dose calculation in prostate brachytherapy.
  • MCPI physically simulates a set of radioactive seeds with arbitrary positions and orientations, merged in a three-dimensional (3D) heterogeneous phantom representing the prostate and surrounding tissue.
  • MCPI is more than 103 and 104 times faster than MCNP5 for prostate dose calculations using 2- and 1-mm voxels, respectively.
  • Ignoring the interseed attenuation effect or slightly varying the prostate tissue composition may lead to 6% decreases of D100, the dose delivered to 100% of the prostate.
  • The presence of calcifications, covering 1%-5% of the prostate volume, decreases D80, D90, and D100 by up to 32%, 37%, and 58%, respectively.
  • In conclusion, sub-minute dose calculations, taking into account all dosimetric effects, are now possible for more accurate dose planning and dose assessment in prostate brachytherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28524439.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Absorption coefficient / Ancillary equipment / Anisotropy / Brachytherapy / Compton scattering / Dosimetry / Medical imaging / Monte Carlo methods / Phase space methods / Photon scattering / Photons / Therapeutic applications, including brachytherapy / Tissues / biological organs / biological tissues / brachytherapy / dosimetry / iodine / palladium / phantoms
  •  go-up   go-down


67. Winkley R: Starting out - I enabled a patient to make his own decision on cancer trial. Nurs Stand; 2010 Jan 27;24(21):28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Starting out - I enabled a patient to make his own decision on cancer trial.
  • This involved him taking three new treatments for his metastatic prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28010646.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Karakunnel JJ, Gulley JL, Arlen P, Mulquin M, Wright J, Turkbey IB, Choyke P, Figg WD, Dahut W: Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC).
  • : 5141 Background: There is no standard therapy for prostate cancer patients who have progressed following docetaxel therapy.
  • Grade 3 toxicities included vomiting (2), prolonged QTc interval (1) and muscle weakness (3), weight loss (3), dehydration (4), fatigue (6), hypoxia (1), renal failure (1), transaminitis (3), and anorexia (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964432.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Hunt DC, Soliman H, Sankreacha R, Morton G: Sci-Sat AM(2): Brachy-09: Investigation of catheter displacement in HDR prostate brachytherapy. Med Phys; 2008 Jul;35(7Part3):3417
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sci-Sat AM(2): Brachy-09: Investigation of catheter displacement in HDR prostate brachytherapy.
  • During prostate cancer treatment with HDR brachytherapy, catheters are inserted into the prostate.
  • The purpose of this study was to investigate the consequences of catheter displacement on prostate coverage and critical structure avoidance.
  • DVH data was calculated for the prostate, rectum, urethra, and bladder.
  • Prostate V100 decreased from 99% to 36% over the ten patients studied.
  • Every effort should be made to ensure that the catheters do not move during prostate treatment.
  • Larger shifts will have a serious impact on the dose delivered to the prostate and to sensitive normal structures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512878.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Brachytherapy / Cancer / Dosimetry
  •  go-up   go-down


70. Chow JCL, Markel D, Jiang R: Technical Note: Calculation of normal tissue complication probability using Gaussian error function model. Med Phys; 2010 Sep;37(9):4924-4929

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seven-beam intensity modulated radiation therapy (IMRT) treatment planning was performed in three patients with small(40cm3), medium (53cm3), and large (87cm3) prostate volume, selected from a group of 20 patients.
  • Rectal dDVH varying with the interfraction prostate motion along the anterior-posterior direction was determined by the treatment planning system (TPS) and modeled by the Gaussian error function model for the three patients.
  • The variations in the rectal NTCP with the prostate motion and volume were studied.
  • RESULTS: For the ranges of prostate motion of 8-2, 4-8, and 4-3 mm along the anterior-posterior direction for the small, medium, and large prostate patient, the rectal NTCP was determined varying in the ranges of 4.6%-4.8%, 4.5%-4.7%, and 4.6%-4.7%, respectively.
  • Moreover, the rectal NTCP was found varying in about ±0.2% with the interfraction prostate motion along the anterior-posterior direction in the radiation treatment.
  • The dependence of the variation in the rectal NTCP with the interfraction prostate motion on the prostate volume was found to be more significant in the patient with larger prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524560.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Databases / Digital radiography / Distribution theory and Monte Carlo studies / Dosimetry / Gaussian distribution / Gaussian error function / Gold / Intensity modulated radiation therapy / Medical treatment planning / NTCP calculation / Radiation treatment / Therapeutics / Tissues / Treatment strategy / biological organs / biological tissues / dose-volume histogram / interfraction prostate motion / physiological models / probability / prostate IMRT / radiation therapy
  •  go-up   go-down


71. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Ravents CX, Cataln R, Revents J: Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. Int J Biol Markers; 2005 Apr - Jun;20(2):119-222
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.
  • We analyzed the behavior of serum FT in patients with prostate cancer receiving androgen deprivation therapy (ADT) and correlated FT with total testosterone (TT).
  • METHODS: Serum levels of TT and FT were determined in 191 patients with prostate cancer in a cross-sectional study.
  • The remaining 135 patients with advanced prostate cancer on three-month LHRH agonist treatment comprised the study group.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207137.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


72. Ludlum E, Mu G, Weinberg V, Roach M 3rd, Verhey LJ, Xia P: An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodesa). Med Phys; 2007 Dec;34(12):4750-4756

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodesa).
  • Concurrent treatment of the prostate and the pelvic lymph nodes encounters the problem of the prostate gland moving independently from the pelvic lymph nodes on a daily basis.
  • The purpose of this study is to develop a leaf-tracking algorithm for adjustment of IMRT portals without requirement of online dose calculation to account for daily prostate position during concurrent treatment with pelvic lymph nodes.
  • A leaf-shifting algorithm was developed and programmed to adjust the positions of selected MLC leaf pairs according to prostate movement in the plane perpendicular to each beam angle.
  • IMRT plans from five patients with concurrent treatment of the prostate and pelvic lymph nodes were selected to test the feasibility of this algorithm by comparison with isocenter-shifted plans, using defined dose endpoints.
  • When the prostate moved 0.5, 1.0, and 1.5 cm along the anterior/posterior direction, the average doses to 95% of the prostate (D95%) for the iso-shift plans were similar to the MLC-shift plans, (54.7, 54.4, and 54.1 Gy versus 54.5, 54.3, and 53.9 Gy, respectively).
  • Compensation for prostate movement along the superior/inferior direction was more complicated due to a limiting MLC leaf width of 1.0 cm.
  • In order to concurrently treat the prostate and pelvic lymph nodes with the prostate moving independently, shifting selected MLC leaf pairs may be a more practical adaptive solution than shifting the patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2007 American Association of Physicists in Medicine.
  • (PMID = 28523810.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Dosimetry / IMRT / Intensity modulated radiation therapy / Medical imaging / Multileaf collimators / Radiation therapy / Radiation treatment / Therapeutics / Treatment strategy / Ultrasonography / Vesicles / adaptive radiotherapy / biological tissues / biomechanics / image-guided radiotherapy / leaf-tracking algorithm / patient monitoring / prostate / radiation therapy
  •  go-up   go-down


73. Perez SA, Bisias S, Kallinteris NL, Ardavanis A, Georgakopoulou KG, Apostolikas N, Thanos A, Papamichail M, von Hofe E, Baxevanis CN: Results from the first phase I clinical study of the novel Ii-Key/HER2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results from the first phase I clinical study of the novel Ii-Key/HER2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
  • Herein, we present the results of the first phase I clinical trial of the Ii-Key/HER-2/neu(776-790) (AE37) vaccine in patients (pts) with prostate cancer.
  • METHODS: Androgen-dependent (AD) and androgen-independent (AI) pts with HER-2/neu+ (IHC: 1-3) prostate adenocarcinomas were eligible.
  • Toxicity and side effects beyond grade-2 were not observed.
  • AE37 is also capable of eliciting potent and specific immunologic responses in prostate cancer pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962063.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Shore ND, Savulsky C, Mis R, Karlin G, Marberger M, Leuratti C, Kaisary A: Phase III efficacy and safety trial of a new leuprolide acetate 3.75 mg depot formulation in prostate cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16152

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III efficacy and safety trial of a new leuprolide acetate 3.75 mg depot formulation in prostate cancer patients.
  • : e16152 Background: Androgen suppression is the standard palliative treatment for metastatic, localized or locally advanced prostate cancer.
  • This phase III, open-label, international multicenter clinical study was conducted to investigate the efficacy and safety profile of a new formulation of leuprolide acetate (Lutrate 3.75mg Depot) in suppressing testosterone levels in prostate cancer patients.
  • METHODS: 160 patients with prostate cancer who could benefit from androgen deprivation therapy received single intramuscular injections of Lutrate 3.75 mg Depot every 28 days for a total of six doses.
  • CONCLUSIONS: The results of this study demonstrate that Lutrate 3.75 mg Depot is as effective as presently marketed one-month leuprolide acetate formulations in establishing and maintaining testosterone concentration below castration levels in prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963420.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Sanders HR, Li H, Qu KZ, Zhang ZJ, Sferruzza AD, Albitar M: Intragenic expression profile in tissue and plasma for the detection of TMPRSS2 rearrangements associated with prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5162

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intragenic expression profile in tissue and plasma for the detection of TMPRSS2 rearrangements associated with prostate cancer.
  • : 5162 Background: TMPRSS2 gene rearrangements have been reported in 40%-85% of prostate cancer (PCa) patients and have not been found in normal individuals or those with benign prostate hyperplasia (BPH).
  • The 3':5' ratios were <30 in 47% and ≥30 in 6.7% PCa plasma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964480.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Winkfield KM, Chen M, Dosoretz DE, Salenius SA, Katin MJ, Ross R, D'Amico AV: Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. J Clin Oncol; 2009 May 20;27(15_suppl):5068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.
  • : 5068 Purpose: We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer.
  • METHODS: The study cohort was comprised of 4,880 men with clinical stage T1-3N0M0 prostate cancer and minimum follow-up of 2 years who underwent brachytherapy-based treatment at 20 centers within the 21st Century Oncology consortium.
  • CONCLUSIONS: African-American and Hispanic race as compared to white race appear to confer a higher risk of mortality following brachytherapy-based treatment in men with localized or locally advanced prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964249.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Aubry JF, Cheung J, Yom S, Gottschalk A, Aubin M, Morin O, Descovich M, Beaulieu L, Pouliot J: Sci-Thurs PM: Delivery-12: Correction and calibration of megavoltage cone-beam CT images for the calculation of the dose of the day. Med Phys; 2008 Jul;35(7Part2):3401

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To show that accurate dose calculations can be achieved with megavoltage cone-beam CT (MVCBCT) images of head-and-neck (H&N) and prostate sites, allowing the verification of the daily dose distribution received by these patients.
  • MVCBCT images of six H&N and two prostate patients were acquired weekly during the course of their treatment.
  • Several regions of interest were contoured including: the prostate and rectum and the spinal cord and parotids.
  • For prostate patients on one fraction the dose received by 95% of the prostate diminished by 3%.
  • CONCLUSION: MVCBCT can be used to verify daily dose distributions for H&N and prostate patients.
  • Underdosage of the prostate and the dosimetric consequences of volume changes in rectum and bladder were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512819.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Calibration / Computed tomography / Medical image artifacts / Medical imaging / Tissues
  •  go-up   go-down


78. Storhoff J, Lubben T, Lefebvre P, Holzman T: Detection of prostate cancer recurrence using an ultrasensitive nanoparticle-based PSA assay. J Clin Oncol; 2009 May 20;27(15_suppl):e16146

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of prostate cancer recurrence using an ultrasensitive nanoparticle-based PSA assay.
  • : e16146 Approximately 400,000 men are diagnosed each year with prostate cancer worldwide, and many of those patients undergo radical prostatectomy in an attempt to cure the disease.
  • Although prostatectomy is effective for a majority of patients, approximately 15 to 40 % will experience prostate cancer recurrence within 5 years, and a majority of those patients will die from the disease (JAMA. 2008;299:2760-2769).
  • Currently, prostate cancer recurrence is determined by monitoring prostate specific antigen (PSA) levels in patients following treatment, and those patients whose PSA levels rise above the clinical cutoff of 200 pg/mL PSA are defined as having recurrent prostate cancer.
  • For those that do recur and have high PSA doubling times, early salvage radiotherapy confers a significant increase in prostate cancer specific survival (1).
  • In this presentation, we describe the application of this technology in monitoring PSA levels in patients that are approximately 400 fold below the current clinical cutoff as a means of diagnosing prostate cancer recurrence at a much earlier timepoint than current assays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963430.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Culig Z, Oh SJ, Santer FR, Puhr M, Steiner H, Hobisch A: Effects of sorafenib on proliferation of hormone-sensitive and hormone-insensitive prostate cancer cells. J Clin Oncol; 2009 May 20;27(15_suppl):e16092

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of sorafenib on proliferation of hormone-sensitive and hormone-insensitive prostate cancer cells.
  • : e16092 Background: Sorafenib is a multi-targeted kinase inhibitor approved for treatment of renal and hepatocellular cancer.
  • In patients with castration therapy-resistant prostate cancer sorafenib treatment is associated with discordant prostate-specific antigen (PSA) and clinical responses, possibly due to an effect on PSA expression.
  • The mechanisms of its action in advanced prostate tumors are not investigated so far.
  • The aim of the present study was to evaluate the effects of sorafenib in androgen-sensitive (LNCaP) and -insensitive (PC 3) prostate cancer cell lines.
  • In addition, Mcl-1 protein, that is frequently overexpressed in prostate cancer, was down-regulated by sorafenib in both cellular models.
  • CONCLUSIONS: Sorafenib caused inhibition of growth of prostate cancer cells regardless of their androgen sensitivity.
  • Its inhibitory effects on cyclin- dependent kinase 2 and Mcl-1 imply that sorafenib regulates cell cycle progression and apoptosis in prostate cancer.
  • On the basis of these results experiments with chemotherapy-resistant prostate cells are being performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963082.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Kaliks-Guendelmann R, Santi P, Cardoso A, Del Giglio A: Complete androgen blockade as second-line hormone manipulation and delay of chemotherapy in metastatic prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete androgen blockade as second-line hormone manipulation and delay of chemotherapy in metastatic prostate cancer.
  • : e16141 Background: Complete androgen blockade (CAB) after failure of castration or androgen receptor blocker (ARB) has not shown to prolong survival in patients with metastatic prostate cancer, unlike docetaxel-based chemotherapy.
  • METHODS: We performed a retrospective analysis of all patients with metastatic prostate cancer treated with CAB as second-line hormone manipulation in a single institution after September 2005.
  • We identified 78 patients and evaluated correlations of prostate specific antigen (PSA), Gleason scores, age, type and length of first-line hormone manipulation with OS and PFS during CAB.
  • We did not find any correlation of PFS with type of first-line hormone manipulation (castration vs ARB, p = 0.10), age group (≤70 or >70 years old, p = 0.10), level of PSA at diagnosis (≤50 or >50 ng/mL, p = 0.17) or length of first-line hormone manipulation (≤14m vs >14 m, p = 0.78).
  • There was no significant correlation between PFS and Gleason score at diagnosis (score ≤7 or >7, p = 0.25), nor between the level of testosterone at the beginning of CAB and PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963432.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Hirsch J, Nelius T, Pfarr C, De Riese W, Wieland I, Filleur S: Deleted in cancer 1: Search for a function in prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16095

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deleted in cancer 1: Search for a function in prostate cancer.
  • : e16095 Background: Deleted In Cancer 1 (DICE1/INTS6) gene was recently identified to colocalize with the microsatellite marker D13S284 in 13q14.3, a region frequently affected by allelic deletion in many solid tumors including prostate cancer (PrCa).
  • METHODS: Expression of DICE1 was evaluated by Northern Blot in PrCa cell lines LNCap, DU145, PC3, PC3ml and CPTX1532 and compared to expression level in normal prostate cell line NPTX1532.
  • RESULTS: Markedly decreased DICE1 mRNA levels were detected in PrCa cell lines LNCap, DU145, PC3 and PC3ml as well as CPTX1532 as compared to NPTX1532, a cell line derived from normal prostate tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963087.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Singal R, Navarro L, Gordian E, Ramachandran K, Reis I, Manoharan M, Soloway M: Aberrant promoter methylation in serum of prostate cancer patients and controls. J Clin Oncol; 2009 May 20;27(15_suppl):e16046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant promoter methylation in serum of prostate cancer patients and controls.
  • : e16046 Background: The current screening method for prostate cancer (PC), which is based on prostate specific antigen (PSA) level lacks specificity and sensitivity.
  • METHODS: 89 PC patients, 59 with prostatitis (PT) and 104 with benign prostatic hyperplasia (BPH) were enrolled.
  • CONCLUSIONS: Our results suggest that aberrant promoter methylation of GSTPi in serum is a potential biomarker for prostate cancer in whites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963020.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Giri VN, Hughes L, Ruth K: Met160Val TMPRSS2 gene polymorphism and early onset prostate cancer in high-risk men. J Clin Oncol; 2009 May 20;27(15_suppl):5000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Met160Val TMPRSS2 gene polymorphism and early onset prostate cancer in high-risk men.
  • : 5000 Background: The TMPRSS2-ERG gene fusion has been found in over 50% of prostate tumors and its role is being characterized in various clinical settings.
  • This SNP needs clinical characterization in men at high risk for prostate cancer (PCA) (men with a family history [FH] of PCA and African American [AA] men) to determine the role in personalizing PCA early detection.
  • The Prostate Cancer Risk Assessment Program (PRAP) is a prospective screening program for high risk men.
  • Here we evaluated the Met160Val SNP (rs12329760) in the TMPRSS2 gene with respect to race, FH of PCA, and time to PCA diagnosis.
  • Cox models were used for time to PCA diagnosis by risk genotype.
  • Among 183 White men with familial PCA with > one follow-up visit, those with the CT/TT genotypes were found to have a significantly earlier time to PCA diagnosis vs. the CC genotype (p = 0.0058).
  • No trends were seen among AA men for time to PCA diagnosis for any of the Met160Val SNP genotypes.
  • CONCLUSIONS: The T-allele of the Met160Val variant in the TMPRSS2 gene may be informative of time to PCA diagnosis among White men who have a FH of PCA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962898.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Munbodh R, Tagare HD, Chen Z, Jaffray DA, Moseley DJ, Knisely JPS, Duncan JS: 2D-3D registration for prostate radiation therapy based on a statistical model of transmission images. Med Phys; 2009 Oct;36(10):4555-4568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2D-3D registration for prostate radiation therapy based on a statistical model of transmission images.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 American Association of Physicists in Medicine.
  • (PMID = 28525073.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 2D-3D registration / Computed radiography / Computed tomography / Cone beam computed tomography / Digital radiography / Distribution theory and Monte Carlo studies / Gaussian distribution / Medical X-ray imaging / Medical image noise / Medical imaging / Photons / Poisson distribution / Probability theory / Radiography / Registration / Statistical model calculations / Therapeutic applications, including brachytherapy / biological organs / computerised tomography / cone-beam CT / correlation methods / diagnostic radiography / image registration / maximum likelihood / maximum likelihood estimation / medical image processing / phantoms / photon counting / portal images / radiation therapy / setup verification
  •  go-up   go-down


85. Yuan J, Orlandi F, Jefferson M, Li H, Gallardo H, Ku G, Wolchok J, Scher H, Allison J, Slovin SF: Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi). J Clin Oncol; 2009 May 20;27(15_suppl):e16149

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi).
  • Recent data [Proc Amer Soc Clin Onc, Abstr#5004, 2008] from castrate metastatic PC pts suggested that Ipi was active but was associated with grade 3 autoimmune adverse events (AEs), such as colitis, hepatitis, hypophysitis or rash, which required high dose steroids.
  • Pts with grade (gd) 0/1/2 tox were termed "low tox" while those with gd 3/4 tox were "high tox".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963424.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Fallavollita P, Karim Aghaloo Z, Burdette EC, Song DY, Abolmaesumi P, Fichtinger G: Registration between ultrasound and fluoroscopy or CT in prostate brachytherapy. Med Phys; 2010 Jun;37(6Part1):2749-2760

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Registration between ultrasound and fluoroscopy or CT in prostate brachytherapy.
  • PURPOSE: In prostate brachytherapy, transrectal ultrasound (TRUS) is used to visualize the anatomy, while implanted seeds can be visualized by fluoroscopy.
  • In human patient data, C-arm fluoroscopy images showed 81 radioactive seeds implanted inside the prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512962.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Brachytherapy / Computed tomography / Dosimetry / Fluoroscopy / Image reconstruction / Medical image noise / Medical image reconstruction / Medical imaging / Radiography / Reconstruction / Registration / Therapeutic applications, including brachytherapy / Ultrasonography / X-ray imaging / biomedical ultrasonics / brachytherapy / computerised tomography / diagnostic radiography / fluoroscopy / image reconstruction / image registration / medical image processing / phantoms / prostate brachytherapy / registration / ultrasound
  •  go-up   go-down


87. Brassell SA, Raymundo E, Chen Y, Zhao J: Impact of Asian American race on prostate cancer outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):5165

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Asian American race on prostate cancer outcomes.
  • : 5165 Background: The global increased incidence of prostate cancer (CaP) is of growing concern, notably in Asia where a 118% rise has been documented.
  • METHODS: Men registered into the Center for Prostate Disease Research multi-center military national database from 1989-2007 with biopsy-proven CaP and categorized as Asian American, Caucasian, or African American descent were included.
  • At diagnosis, Asian Americans had lower clinical stage (p<0.0001) but worse biopsy grade (p = 0.0006) than other groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964504.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. King RP, Anderson RS, Kandagatla KK: Comment on "Quantifying the interplay effect in prostate IMRT delivery using a convolution-based method" [Med. Phys., - (2008)]. Med Phys; 2008 Dec;35(12):5955-5956

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comment on "Quantifying the interplay effect in prostate IMRT delivery using a convolution-based method" [Med. Phys., - (2008)].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28525125.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Conformal radiation treatment / Dose-volume analysis / Dosimetry / Dosimetry/exposure assessment / Dynamic wedges / Intensity modulated radiation therapy / Medical imaging / Medical physics / Medical treatment planning / Philosophy of science / Radiation therapy / Systems analysis / Therapeutic applications, including brachytherapy / Therapeutics / biological organs / cancer / convolution / dosimetry / radiation therapy / telemedicine / tumours
  •  go-up   go-down


89. Fisch M, Lee JW, Manola J, Wagner L, Chang V, Gilman P, Lear K, Baez L, Cleeland C: Survey of disease and treatment-related symptoms in outpatients with invasive cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study). J Clin Oncol; 2009 May 20;27(15_suppl):9619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survey of disease and treatment-related symptoms in outpatients with invasive cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study).
  • METHODS: This large prospective study by the Eastern Cooperative Oncology Group (ECOG) enrolled pts with invasive cancer of the breast, prostate, colon/rectum or lung regardless of phase of care or stage of disease.
  • RESULTS: 3124 patients were enrolled (90% from community clinics) and 3077 were analyzable with 1524 breast (50%), 715 colorectal (23%), 518 lung (17%), and 320 prostate (10%) pts.
  • Of the 849 pts receiving anti-cancer treatment for metastatic disease, half had 2 or more metastatic sites with 75% receiving cytotoxic chemotherapy.
  • Clinicians judged lung cancer patients' symptoms to be the most difficult to manage (p<0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963878.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Maroto-Rey P, Sala N, Mora J, Villavicencio H, Esquena S, Robert L, Perez J, Mazarico J, Barnadas A: Circulating chromogranin A as a marker for poor-prognosis hormone refractory prostate cancer without neuroendocrine features: Prospective analyses of a cohort of patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16130

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating chromogranin A as a marker for poor-prognosis hormone refractory prostate cancer without neuroendocrine features: Prospective analyses of a cohort of patients.
  • : e16130 Background: Some patients may develop hormone refractory prostate (HRPC) cancer with neuroendocrine features, although they were not recognizable in the initial biopsy.
  • We analyzed the time to hormone-refractory disease since diagnosis, and overall survival, as well as pattern of relapse (visceral vs. nonvisceral disease).
  • CONCLUSIONS: The analysis of this cohort of patients suggests that serum chromogranine A correlates with other known adverse prognosis factors of survival in prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963370.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG: A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5156

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer.
  • DLT's observed: L2: Grade 4 Neutropenia (1 pt); L3-5 None.
  • Of the 3 patients treated at L6, 2 developed DLTs (febrile neutropeina, grade 4 neutropenia) precluding further dose escalation.
  • Other Grade 3/4 toxicities observed after cycle 1 included deep venous thrombosis (2 pts), grade 3 neutropenia (2 pts), grade 3 facial edema (1 pt) Of 31 pts evaluable for post treatment PSA declines; 8/17 (47%) untreated pts 7/14 (50%) previoustly treated pts had a >50% decline in PSA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Cetnar JP, Rosen MA, Vaughn DJ, Haas NB, Troxel AB, Song H, Adluru G, Flaherty KT, O'Dwyer PJ, Amaravadi RK: Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC).
  • Six patients received sorafenib 200mg BID and remaining patients received sorafenib 400 mg BID if <4/6 patients had grade 4 neutropenia.
  • Grade 3 adverse events were neutropenia (77%), hand-foot syndrome (23%), anemia (15%), nausea (8%), and rash (8%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Humphreys MR, Ma C, Sridhar SS: Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients.
  • Bivariate Cox Proportional-Hazards regression was used to test the association of age at diagnosis while adjusting for a covariate, with significant covariates entered into multivariate models.
  • Pts <55 and ≥75 presented with advanced stage at diagnosis and progressed to bone metastasis earlier.
  • Pts ≥75 had decreased performance status, more comorbidities, higher PSA at diagnosis, shorter duration of hormone sensitive disease, and were less likely to receive chemotherapy than pts <75.
  • In multivariate analysis with age as a categorical variate, ECOG 3-4 (HR 2.65), time from diagnosis to both HRPC (HR 0.78) and bone metastasis (HR 0.80), and duration of response to androgen ablation (HR 0.86) remained highly predictive.
  • CONCLUSIONS: Age at diagnosis influences OS in HRPC with a bimodal survival curve.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962997.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Saad F, Smith MR, Egerdie B, Tammela TL, Feldman RA, Heracek J, Szwedowski M, Ke C, Leder B, Goessl C: Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC). J Clin Oncol; 2009 May 20;27(15_suppl):5056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962972.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Dale W, Bilir SP, Hemmerich J, Basu A, Meltzer DO: Logical inconsistency in comorbid health state preference assessment for prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Logical inconsistency in comorbid health state preference assessment for prostate cancer.
  • A particular challenge in the aging population with high cancer risk is maintaining logical consistency when evaluating comorbid utilities.
  • Determining why or by whom this condition fails could improve elicitation practices and CEA for cancer and comorbid diseases.
  • METHODS: Men were surveyed at the time of prostate biopsy.
  • The most prevalent health states associated with prostate cancer in the SEER database were chosen for assessment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963806.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Priolo C, Loda M: Unraveling the metabolome in prostate tumorigenesis: Effects by an oncogenic isopeptidase. J Clin Oncol; 2009 May 20;27(15_suppl):e16148

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unraveling the metabolome in prostate tumorigenesis: Effects by an oncogenic isopeptidase.
  • : e16148 Background: Cancer cells undergo fundamental changes in their metabolism, including a higher rate of glycolysis and an increase in de novo fatty acid synthesis.
  • The high incorporation of glucose into tumor cells has already been exploited in cancer diagnostics with the generation of the FDG-PET scan technology.
  • However, some tumors including those arising in the prostate are less prone to FDG-PET imaging and could benefit from other imaging techniques based on alternative metabolic features.
  • We asked whether prostate epithelial cell transformation driven by specific oncogenes results in a typical metabolic profiling, whose characterization may be useful to improve diagnostics and to address new therapeutics.
  • METHODS: Normal prostate epithelial cells (RWPE-1 and PrEC) were transformed by overexpressing known oncogenes, such as the protein kinase AKT1 and the de-ubiquitinating enzyme (isopeptidase) USP2a.
  • RESULTS: We integrated data from different high-throughput technologies to map metabolic changes induced during prostate tumorigenesis by genes that are often altered in prostate cancer.
  • Metabolic profiling analysis of human prostate tumors is currently ongoing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963423.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Nath R, Bice WS, Butler WM, Chen Z, Meigooni AS, Narayana V, Rivard MJ, Yu Y: AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. Med Phys; 2009 Nov;36(11):5310-5322
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137.
  • During the past decade, permanent radioactive source implantation of the prostate has become the standard of care for selected prostate cancer patients, and the techniques for implantation have evolved in many different forms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 American Association of Physicists in Medicine.
  • (PMID = 28525096.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Biomedical imaging / Biomedical modeling / Brachytherapy / Cancer / Computed tomography / Dose-volume analysis / Dosimetry / Dosimetry/exposure assessment / Medical imaging / Medical treatment planning / Radiopharmaceuticals / Robotics / Therapeutic applications, including brachytherapy / Ultrasonography / biological organs / biomedical imaging / brachytherapy / cancer / dosimetry / prescription / prostate / radioactive tracers / reporting / tumours
  •  go-up   go-down


98. Libener R, Montefiore F, Bonini F, Ruggero L, Maffezzini M, Puntoni M, Nanni L, Paganuzzi M, Puntoni R, Betta P: Sensitivity and specificity of osteopontin (OPN) versus prostate-specific antigen (PSA) in prostate carcinoma (PCa): A case- control study. J Clin Oncol; 2009 May 20;27(15_suppl):e16082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of osteopontin (OPN) versus prostate-specific antigen (PSA) in prostate carcinoma (PCa): A case- control study.
  • METHODS: Serum total PSA using a chemiluminescent immunoassay system (Hybritech PSA, DxI Beckman Coulter, Inc.) and plasma OPN using an ELISA technique (R&D Systems, Inc.) were measured in 263 male subjects referred for diagnostic prostate biopsy, including 167 control patients with benign prostate pathology (mean age: 65.30; median age: 66; SD: 6.80; range 46-83) and 96 PCa patients (mean age: 66.80; median age: 68; SD: 7.90; range 47-86).
  • The ROC curve showed that OPN was not a marker that enabled the discrimination between PCa and non-cancer patients.
  • A follow-up of the patients involved is ongoing in order to assess a possible prognostic role of the two markers. (The study was funded by the Alessandria branch of the Italian League against Cancer through a grant from the Cassa di Risparmio di Alessandria Foundation) No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963103.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Carreca I, Bellomo F, Burgio S, D'Alia P, Piazza D, Russo S, Balducci L: Impact of VEGF and CgA as new predictive tools in management of elderly hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of VEGF and CgA as new predictive tools in management of elderly hormone-refractory prostate cancer (HRPC) patients.
  • : e16070 Background: Prostate cancer is one of the most frequent malignancy in men of the Western countries.
  • The identification of new predictive factors of drug activity is crucial for elderly cancer patients, who need a particular selection according to prediction of efficacy and safety by pre-treatment parameters.
  • Several prostate cancers show focal neuroendocrine (NE) spots and CgA seems to be associated to NE phenotype both in tissue and in circulation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963036.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Kehwar TS, Jones HA, Huq MS, Beriwal S, Benoit RM, Smith RP: Effect of edema associated with C131s prostate permanent seed implants on dosimetric quality indices. Med Phys; 2009 Aug;36(8):3536-3542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of edema associated with C131s prostate permanent seed implants on dosimetric quality indices.
  • This study was designed to investigate the effect of prostatic edema on various dosimetric quality indices following transperineal permanent C131s seed implant.
  • Thirty-one patients with early prostate cancer, who received C131s permanent seed implant, were included in this study.
  • Transrectal ultrasound (U.S.) was used to measure the preimplant prostate volume and pre- and postneedle implant volumes, and postimplant CT images were used to obtain postimplant prostate volumes at days 0, 14, and 28 for all patients.
  • The magnitude of edema was determined by comparing the preneedle and postimplant prostate volumes, which was used to compute the half life of the edema using the least-squares method.
  • Dose volume histograms were generated for each set of volumes to determine the percentage of the prostate volume that received a dose equal to or greater than the prescribed dose to compute the quality index (V100) and fractional D90 (FD90).
  • On the other hand, the mean values of V100 and FD90 increased with increasing postimplant time and attained optimal values when postimplant volume reached the original volume of the prostate.
  • The short half life C131s radioactive source delivered about 85% of the prescribed dose before the prostate reached its original volume.
  • Therefore, improvement in V100 and FD90 due to edema decay does not improve the physical dose delivery to the prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 American Association of Physicists in Medicine.
  • (PMID = 28541608.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 131Cs prostate seed implant / Biomedical engineering / Brachytherapy / Cancer / Computed tomography / Computer software / Dose-volume analysis / Dosimetry / FD90 / Isotopes / Medical imaging / Radioactive sources / Ultrasonic effects / Ultrasonography / biological organs / biomedical ultrasonics / computerised tomography / dose volume histogram / dosimetry / prostatic edema / prosthetics / quality index
  •  go-up   go-down






Advertisement